Anti-inflammatory effects of hepatocyte growth factor on the vicious cycle of macrophages and adipocytes

Hypertension Research

Volumn 37, Issue 6, 2014, Pages 500-506

  Kusunoki, Hiroshi ^a   Taniyama, Yoshiaki ^a   Otsu, Rei ^a   Rakugi, Hiromi ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

adipose tissues; chronic inflammation; hepatocyte growth factor

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN E; ASPARTATE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SCATTER FACTOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; CYTOKINE;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COCULTURE; CONTROLLED STUDY; DENSITY; EPIDIDYMIS FAT; FATTY LIVER; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIPID BLOOD LEVEL; LIPID DIET; LIPID STORAGE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROADIPOCYTE; PROTEIN BLOOD LEVEL; UPREGULATION; ANIMAL; CELL CYCLE; CELL LINE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HYPERTENSION; KNOCKOUT MOUSE; METABOLISM; PARACRINE SIGNALING; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; TRANSGENIC MOUSE;

ADIPOCYTES; ADIPONECTIN; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOLIPOPROTEINS E; CELL CYCLE; CELL LINE; COCULTURE TECHNIQUES; CYTOKINES; DISEASE MODELS, ANIMAL; HEPATOCYTE GROWTH FACTOR; HYPERTENSION; IN VITRO TECHNIQUES; MACROPHAGES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PARACRINE COMMUNICATION; PHENOTYPE;

EID: 84901983235     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2014.41     Document Type: Article

References (36)

1. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in thedevelopment of obesity-related insulin resistance. J Clin Invest 2003; 112:1821-1830.
2. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity isassociated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796-1808.
3. Hursting SD, Hursting MJ. Growth signals, inflammation, and vascular perturbations:mechanistic links between obesity, metabolic syndrome, and cancer. ArteriosclerThromb Vasc Biol 2012; 32: 1766-1770.
4. Taniyama Y, Azuma J, Iekushi K, Sanada F, Iwabayashi M, Kusunoki H, Okayama K, Otsu R, Rakugi H, Morishita R. The HGF/c-Met Receptor System Under PathologicalConditions. Immun Endocr Metab Agents Med Chem 2012; 12: 122-129.
5. Sanada F, Taniyama Y, Azuma J, Iekushi K, Dosaka N, Yokoi T, Koibuchi N, Kusunoki H, Aizawa Y, Morishita R. Hepatocyte growth factor, but not vascularendothelial growth factor, attenuates angiotensin II-induced endothelial progenitor cellsenescence. Hypertension 2009; 53: 77-82.
6. Sanada F, Taniyama Y, Iekushi K, Azuma J, Okayama K, Kusunoki H, Koibuchi N, Doi T, Aizawa Y, Morishita R. Negative action of hepatocyte growth factor/c-Met system onangiotensin II signaling via ligand-dependent epithelial growth factor receptor degradationmechanism in vascular smooth muscle cells. Circ Res 2009; 105: 667-675.
7. Shimizu K, Taniyama Y, Sanada F, Azuma J, Iwabayashi M, Iekushi K, Rakugi H, Morishita R. Hepatocyte growth factor inhibits lipopolysaccharide-induced oxidativestress via epithelial growth factor receptor degradation. Arterioscler Thromb Vasc Biol2012; 32: 2687-2693.
8. Iwabayashi M, Taniyama Y, Sanada F, Azuma J, Iekushi K, Okayama K, Chatterjee A, Rakugi H, Morishita R. Inhibition of Lp(a)-induced functional impairment of endothelialcells and endothelial progenitor cells by hepatocyte growth factor. BiochemBiophys Res Commun 2012; 423: 79-84.
9. Hiratsuka A, Adachi H, Fujiura Y, Yamagishi S, Hirai Y, Enomoto M, Satoh A, Hino A, Furuki K, Imaizumi T. Strong association between serum hepatocyte growth factor andmetabolic syndrome. J Clin Endocrinol Metab 2005; 90: 2927-2931.
10. Tsukagawa E, Adachi H, Hirai Y, Enomoto M, Fukami A, Ogata K, Kasahara A, Yokoi K, Imaizumi T. Independent association of elevated serum hepatocyte growth factor levelswith development of insulin resistance in a 10-year prospective study. Clin Endocrinol(Oxf) 2013; 79: 43-48.
11. Yvan-Charvet L, Quignard-Boulangé A. Role of adipose tissue renin-angiotensin systemin metabolic and inflammatory diseases associated with obesity. Kidney Int 2011; 79:162-168.
12. Skurk T, van Harmelen V, Hauner H. Angiotensin II stimulates the release ofinterleukin-6 and interleukin-8 from cultured human adipocytes by activation ofNF-kappaB. Arterioscler Thromb Vasc Biol 2004; 24: 1199-1203.
13. Tsuchiya K, Yoshimoto T, Hirono Y, Tateno T, Sugiyama T, Hirata Y. Angiotensin IIinduces monocyte chemoattractant protein-1 expression via a nuclear factor-kappaBdependentpathway in rat preadipocytes. Am J Physiol Endocrinol Metab 2006; 291:E771-E778.
14. Kusunoki H, Taniyama Y, Azuma J, Iekushi K, Sanada F, Otsu R, Iwabayashi M, Okayama K, Rakugi H, Morishita R. Telmisartan exerts renoprotective actions viaperoxisome proliferator-activated receptor-g/hepatocyte growth factor pathway independentof angiotensin II type 1 receptor blockade. Hypertension 2012; 59: 308-316.
15. Giannopoulou M, Dai C, Tan X, Wen X, Michalopoulos GK, Liu Y. Hepatocyte growthfactor exerts its anti-inflammatory action by disrupting nuclear factor-kappaB signaling.Am J Pathol 2008; 173: 30-41.
16. Iekushi K, Taniyama Y, Kusunoki H, Azuma J, Sanada F, Okayama K, Koibuchi N, Iwabayashi M, Rakugi H, Morishita R. Hepatocyte growth factor attenuates transforminggrowth factor-b-angiotensin II crosstalk through inhibition of the PTEN/Aktpathway. Hypertension 2011; 58: 190-196.
17. Coudriet GM, He J, Trucco M, Mars WM, Piganelli JD. Hepatocyte growth factormodulates interleukin-6 production in bone marrow derived macrophages: implicationsfor inflammatory mediated diseases. PLoS One 2010; 5: e15384.
18. Gong R, Rifai A, Tolbert EM, Biswas P, Centracchio JN, Dworkin LD. Hepatocyte growthfactor ameliorates renal interstitial inflammation in rat remnant kidney by modulatingtubular expression of macrophage chemoattractant protein-1 and RANTES. J Am SocNephrol 2004; 15: 2868-2881.
19. Chatterjee A, Kusunoki H, Taniyama Y, Rakugi H, Morishita R. Improvement ofmetabolic syndrome by irbesartan via the PPARg/HGF pathway in apolipoprotein Eknockout mice. Biomed Reports 2013; 1: 65-70.
20. D́ez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin inhuman disease. Eur J Endocrinol 2003; 148: 293-300.
21. Ukkola O, Santaniemi M. Adiponectin: a link between excess adiposity and associatedcomorbidities? J Mol Med (Berl) 2002; 80: 696-702.
22. Ezaki H, Yoshida Y, Saji Y, Takemura T, Fukushima J, Matsumoto H, Kamada Y, WadaA, Igura T, Kihara S, Funahashi T, Shimomura I, Tamura S, Kiso S, Hayashi N. Delayedliver regeneration after partial hepatectomy in adiponectin knockout mice. BiochemBiophys Res Commun 2009; 378: 68-72.
23. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reversesinsulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7:941-946.
24. Okayama K, Azuma J, Dosaka N, Iekushi K, Sanada F, Kusunoki H, Iwabayashi M, Rakugi H, Taniyama Y, Morishita R. Hepatocyte growth factor reduces cardiac fibrosisby inhibiting endothelial-mesenchymal transition. Hypertension 2012; 59: 958-965.
25. Malatino LS, Mallamaci F, Benedetto FA, Bellanuova I, Cataliotti A, Tripepi G, Zoccali C. Hepatocyte growth factor predicts survival and relates to inflammationand intima media thickness in end-stage renal disease. Am J Kidney Dis 2000; 36:945-952.
26. Malatino LS, Cataliotti A, Benedetto FA, Stancanelli B, Bellanuova I, Belluardo P, Bonaiuto L, Tripepi G, Mallamaci F, Castellino P, Zoccali C. Hepatocyte growth factorand left ventricular geometry in end-stage renal disease. Hypertension 2003; 41:88-92.
27. Rehman J, Considine RV, Bovenkerk JE, Li J, Slavens CA, Jones RM, March KL.Obesity is associated with increased levels of circulating hepatocyte growth factor.J Am Coll Cardiol 2003; 41: 1408-1413.
28. Katsuno T, Ozaki T, Saka Y, Furuhashi K, Kim H, Yasuda K, Yamamoto T, Sato W, Tsuboi N, Mizuno M, Ito Y, Imai E, Matsuo S, Maruyama S. Low serum cultured adiposetissue-derived stromal cells ameliorate acute kidney injury in rats. Cell Transplant2013; 22: 287-297.
29. Yasuda K, Ozaki T, Saka Y, Yamamoto T, Gotoh M, Ito Y, Yuzawa Y, Matsuo S, Maruyama S. Autologous cell therapy for cisplatin-induced acute kidney injury by usingnon-expanded adipose tissue-derived cells. Cytotherapy 2012; 14: 1089-1100.
30. Ikegame Y, Yamashita K, Hayashi S, Mizuno H, Tawada M, You F, Yamada K, Tanaka Y, Egashira Y, Nakashima S, Yoshimura S, Iwama T. Comparison of mesenchymal stemcells from adipose tissue and bone marrow for ischemic stroke therapy. Cytotherapy2011; 13: 675-685.
31. Nakagami H, Morishita R, Maeda K, Kikuchi Y, Ogihara T, Kaneda Y. Adipose tissuederivedstromal cells as a novel option for regenerative cell therapy. J AtherosclerThromb 2006; 13: 77-81.
32. Nakagami H, Maeda K, Morishita R, Iguchi S, Nishikawa T, Takami Y, Kikuchi Y, Saito Y, Tamai K, Ogihara T, Kaneda Y. Novel autologous cell therapy in ischemic limbdisease through growth factor secretion by cultured adipose tissue-derived stromalcells. Arterioscler Thromb Vasc Biol 2005; 25: 2542-2547.
33. Kosone T, Takagi H, Horiguchi N, Ariyama Y, Otsuka T, Sohara N, Kakizaki S, Sato K, Mori M. HGF ameliorates a high-fat diet-induced fatty liver. Am J Physiol GastrointestLiver Physiol 2007; 293: G204-G210.
34. Balaban YH, Sumer H, Simsek H, Us D, Tatar G. Metabolic syndrome, non-alcoholicsteatohepatitis (NASH), and hepatocyte growth factor (HGF). Ann Hepatol 2006; 5:109-114.
35. Bertola A, Bonnafous S, Cormont M, Anty R, Tanti JF, Tran A, Le Marchand-Brustel Y, Gual P. Hepatocyte growth factor induces glucose uptake in 3T3-L1 adipocytes throughA Gab1/phosphatidylinositol 3-kinase/Glut4 pathway. J Biol Chem 2007; 282:10325-10332.
36. Araú jo TG, Oliveira AG, Carvalho BM, Guadagnini D, Protzek AO, Carvalheira JB, Boschero AC, Saad MJ. Hepatocyte growth factor plays a key role in insulin resistanceassociatedcompensatory mechanisms. Endocrinology 2012; 153: 5760-5769.